Research programme: monoclonal antibodies - Fujirebio

Drug Profile

Research programme: monoclonal antibodies - Fujirebio

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Fujirebio
  • Class Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in Japan
  • 03 Dec 2010 Preclinical trials in Cancer (diagnosis) in Japan (unspecified route)
  • 19 Nov 2010 Pharmacodynamics data from a preclinical trial in Cancer presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top